RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product
RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expected 75 patients in this clinical trial.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306978603/en/
RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege.
“The results from this ongoing international multicenter study are exceeding expectations, showcasing remarkable outcomes. We are profoundly optimistic and incredibly enthusiastic about what the future holds,” said Prof. Dr. med. Dent., Patrick Schmidlin, head of the Division of Periodontology at the University of Zurich, who serves as one of the investigators in RevBio’s pivotal clinical trial. “This breakthrough material promises to open a new chapter in dental care, redefining what is possible in regenerative dentistry.”
RevBio received regulatory and ethics committee approvals for five clinical sites consisting of one in Switzerland, two in Belgium, one in Spain, and one in the United Kingdom. Each site is expected to enroll between 12-25 patients for a total of approximately 75 patients. The investigators who are approved to enroll patients in this clinical trial are Prof. Dr. med. Dent., PhD, Patrick Schmidlin, head of the Department of Periodontology at the University of Zurich, Ana Castro, BDS MSc PhD, Clinical Head Department Periodontology at the Catholic University of Leuven, France Lambert, DDS, PhD, Professor and Head of Periodontology, Oral Surgery, and Implant Surgery at the University of Liege, Arturo Llobell, DDS, MS, a periodontist in private practice in Valencia, Spain, and Azim Malik, BDS, MFDS RCSEd, DipPCD RCSI, DClinDent, MPerio RCSEd, a periodontist and implant specialist in private practice in London, United Kingdom.
When teeth are extracted due to damage from traumatic injuries, tooth decay, or gum disease, the current standard of care consists of multiple staged surgical procedures to restore a patient’s dentition with prosthetic crowns supported by dental implants. Frequently, extraction sites are too large for dental implants to achieve primary stability through conventional mechanical engagement. Instead, patients must undergo a costly, complex, and lengthy process including a preliminary bone grafting surgery before receiving a dental implant. The use of TETRANITE to stabilize an unstable implant will allow for the immediate placement of dental implants which otherwise could not be placed until the initial bone graft has healed to form new bone. As a result, the TETRANITE® biomaterial will help reduce the duration and complexity of these dental implant procedures, lessen patient pain and recovery time, and reduce the overall cost of care thereby providing greater patient access for the treatment of tooth loss.
"The approval to conduct this pivotal clinical trial and the successful enrollment of the first 30 patients is a watershed moment for RevBio," said Alan Pollack, DDS, RevBio’s Senior Director of Dental Clinical Operations. “This clinical trial has the potential to significantly accelerate the timeframe when this promising bone adhesive technology can be used in the field of dentistry.”
About RevBio, Inc.
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of TETRANITE®, a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's TETRANITE technology is not yet approved for commercial use.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250306978603/en/
Contacts
Michael Tiedemann
mtiedemann@revbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Laserfiche Announces 2025 Run Smarter® Award Winners18.3.2025 16:00:00 EET | Press release
Laserfiche — a leading enterprise platform that helps organizations manage their most critical content and workflows — today announced the winners of the 2025 Laserfiche Run Smarter® Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318932755/en/ The awards honor individuals and organizations that yield exceptional business results using Laserfiche. From a state department that revolutionized how it protects the environment to an insurance agency that leapt into action after a hurricane: The winners enhance productivity, foster innovative processes and improve lives with Laserfiche technology. “These honorees are champions of the employee and customer experience,” said Karl Chan, CEO of Laserfiche. “They are leading their industries in transforming how they work using Laserfiche. We are delighted to celebrate their remarkable achievements.” Congratulations to the 2025 Run Smarter Award winners: Angela Goerner, direct
Andersen Global Broadens Reach in Bangladesh with Edge Research18.3.2025 15:30:00 EET | Press release
Andersen Global further expands into Bangladesh through a Collaboration Agreement with valuation and research firm Edge Research, further solidifying its presence in South Asia. Founded in 2017 and based in Dhaka, Edge Research focuses on corporate valuation, due diligence, transaction advisory, and financial analysis for both the public and private sectors. The firm’s expertise spans multiple asset classes and domains, supported by a deep understanding of the Bangladesh market. With a team experienced in working with multinational companies, global banks, and foreign fund managers, Edge Research is uniquely positioned to deliver insights that cater to international and local client needs. “Our team’s deep understanding of the local business market, coupled with a strong emphasis on identifying critical drivers of value, allows us to maintain a competitive edge,” said Managing Partner Asif Khan. “Collaborating with Andersen Global strengthens our ability to deliver independent, globall
DDC Announces Strategy to Create Bitcoin Reserves and Appoints Crypto Asset Expert Alex Yang as Strategic Advisor18.3.2025 15:14:00 EET | Press release
DDC Enterprise, Ltd. (NYSEAM: DDC), (“DayDayCook,” “DDC,” or the “Company”), a leading multi-brand Asian consumer food company, today announced a transformative initiative to adopt Bitcoin as part of its treasury reserves, alongside an announcement that brings seasoned Web3 and Crypto Assets Management Expert Alex Yang to DDC as Strategic Advisor. An investor group will inject up to 100 BTC in exchange for DDC Class A Ordinary shares at a range of $0.50 to $1.25 per share, representing a 100% to 400% premium to recent trading levels. Strategic Alignment with Institutional Confidence “This partnership is a testament to the shared conviction in DDC’s future and the value of Bitcoin and potentially other crypto currencies as a strategic asset,” said Ms. Norma Chu, Chairwoman and CEO of DDC Enterprise. “This strategic decision to launch a bitcoin reserve not only diversifies our balance sheet but also secures a premium-priced equity agreement that reflects our partner’s belief in our long-
Qualcomm Increases Quarterly Cash Dividend18.3.2025 15:00:00 EET | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that its Board of Directors has approved an increase in the Company’s quarterly cash dividend from $0.85 to $0.89 per share of common stock. This dividend increase will be effective for quarterly dividends payable after March 27, 2025, and will raise the annualized dividend payout to $3.56 per share of common stock. Cristiano Amon, President and CEO of Qualcomm Incorporated, said, “We are pleased to announce an increase in our quarterly dividend. Given our long-term growth expectations we provided at our 2024 Investor Day, we remain committed to returning capital to stockholders through a balanced capital return policy, including a baseline of anti-dilutive stock repurchases, and an annualized dividend target of low- to mid-single-digit percentage growth.” About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years
Corpay Cross-Border Grows in Europe with Launch of Luxembourg Office18.3.2025 14:30:00 EET | Press release
Corpay, Inc.*, (NYSE: CPAY), a global leader in corporate payments, is proud to announce its entry into Luxembourg with the establishment of a new office for its Cross-Border business. As part of Corpay’s ongoing expansion in Europe, this significant move aligns with the company’s strategy to enhance its presence in key financial markets worldwide and supports its growth ambitions in the institutional investor and private funds space. “The new Luxembourg office underscores our commitment to supporting the sophisticated needs of this global client base and enables us to provide a localized solution set for our institutional clients that establish their international investment structures in Luxembourg,” says Andrew Shortreid, SVP, Global Institutional Sales, Corpay Cross-Border Solutions. “Luxembourg’s status as a major financial hub in the EMEA region, with nearly 50% of its workforce engaged in financial services or related activities, makes it an ideal location for us. This new branc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom